Athira Pharma, Inc. (NASDAQ:ATHA) Sees Large Growth in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,220,000 shares, a growth of 43.2% from the October 31st total of 1,550,000 shares. Currently, 6.2% of the company’s stock are sold short. Based on an average daily trading volume, of 5,150,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Athira Pharma

Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its position in shares of Athira Pharma by 909.8% during the third quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock valued at $177,000 after buying an additional 357,787 shares during the last quarter. Bristlecone Advisors LLC raised its holdings in Athira Pharma by 295.6% in the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after acquiring an additional 252,200 shares in the last quarter. Invst LLC bought a new stake in shares of Athira Pharma in the 2nd quarter worth approximately $68,000. Forefront Analytics LLC grew its holdings in shares of Athira Pharma by 126.0% during the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Athira Pharma during the 2nd quarter worth approximately $60,000. 57.12% of the stock is owned by institutional investors.

Athira Pharma Trading Up 0.3 %

NASDAQ:ATHA traded up $0.00 during mid-day trading on Friday, hitting $0.66. 242,076 shares of the company’s stock traded hands, compared to its average volume of 1,636,542. The firm has a market capitalization of $25.34 million, a price-to-earnings ratio of -0.23 and a beta of 2.82. The firm has a 50 day moving average of $0.54 and a two-hundred day moving average of $1.86. Athira Pharma has a 12 month low of $0.41 and a 12 month high of $4.30.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05. As a group, equities research analysts expect that Athira Pharma will post -2.35 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Rodman & Renshaw lowered Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. JMP Securities downgraded Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th. Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $5.00 to $0.50 in a research report on Thursday, September 19th. Finally, BTIG Research downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.